BCB Guest Seminar Dr. Gyan Srivastava

Thursday, October 27, 2016
12:00 pm
Floor/Room #: 


Computational approaches to in-silico drug discovery for precision medicine



Recent advancement in genomics tools and technologies has changed the drug-discovery paradigm in an unprecedented way. Biomedical industries and academic institutions are forging new alliances to enable drug target identification based on human genetics and causal human biology to improve personalized health care. The common theme of the new drug-discovery paradigm is to integrate knowledge from human genetics, disease biology and pharmacology. However, there is an unmet need of computational approaches to facilitate such integrative analytical framework for utilizing orthogonal data to identify drug targets for further validation. In this talk, Dr. Srivastava will talk about analytical methods to prioritize drug targets anchored in human genetics.  


About the Presenter:

Dr. Gyan Srivastava is a senior scientist in Genetics and Pharmacogenomics (GpGx) at Merck Research Laboratories, Boston where he is actively involved in leveraging public and internal biomedical data and computational tools to identify new drug targets anchored in human genetics and propose hypotheses for therapeutic interventions. He did his postdoc at Harvard Medical School, where he worked on integrating ‘omics data generated from human postmortem brains with neurodegenerative diseases to elucidate molecular mechanism behind neuropathology of these diseases. During his postdoc research, he identified few genes that are involved in developing Alzheimer’s disease pathology through genetic, epigenetic and transcriptional mechanism. Remarkably some of these genes are involved during early stage of developing pathologies e.g. ~10 years before the actual diagnosis of the disease. Hence these genes could potentially be used as early diagnosis biomarkers. One of these genes has recently been confirmed to carry loss-of-function mutation to lead Alzheimer’s disease in Icelandic population. So Merck and few other companies are actively pursuing this drug-target to block the progression of neurodegeneration. He has published over 40 papers in reputed journals including nature, science, PNAS, PLoS, Bioinformatics, NAR and others.